BR0206919A - Derivados de fator de liberação de hormÈnio de crescimento de longa duração - Google Patents

Derivados de fator de liberação de hormÈnio de crescimento de longa duração

Info

Publication number
BR0206919A
BR0206919A BR0206919-9A BR0206919A BR0206919A BR 0206919 A BR0206919 A BR 0206919A BR 0206919 A BR0206919 A BR 0206919A BR 0206919 A BR0206919 A BR 0206919A
Authority
BR
Brazil
Prior art keywords
growth hormone
hormone release
long
release factor
term growth
Prior art date
Application number
BR0206919-9A
Other languages
English (en)
Inventor
Dominique P Bridon
Nissab Boudjellab
Roger Leger
Martin Robitaille
Lucie Jette
Corinne Benquet
Original Assignee
Conjuchem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Inc filed Critical Conjuchem Inc
Publication of BR0206919A publication Critical patent/BR0206919A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

"DERIVADOS DE FATOR DE LIBERAçãO DE HORMÈNIO DE CRESCIMENTO DE LONGA DURAçãO". Esta invenção refere-se a derivado de fator de liberação de hormónio de crescimento (GRF). Em particular, esta invenção refere-se a derivados de peptídeo de GRF tendo uma meia vida in vivo prolongada, para a promoção da produção de endógeno ou liberação de hormónio de crescimento em seres humanos e animais.
BR0206919-9A 2001-02-02 2002-02-01 Derivados de fator de liberação de hormÈnio de crescimento de longa duração BR0206919A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26642401P 2001-02-02 2001-02-02
PCT/CA2002/000123 WO2002062844A2 (en) 2001-02-02 2002-02-01 Long lasting growth hormone releasing factor derivatives

Publications (1)

Publication Number Publication Date
BR0206919A true BR0206919A (pt) 2004-07-06

Family

ID=23014533

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206919-9A BR0206919A (pt) 2001-02-02 2002-02-01 Derivados de fator de liberação de hormÈnio de crescimento de longa duração

Country Status (10)

Country Link
US (1) US7268113B2 (pt)
EP (1) EP1355941A2 (pt)
JP (3) JP2004520395A (pt)
CN (2) CN101696240A (pt)
AU (1) AU2002233082B2 (pt)
BR (1) BR0206919A (pt)
CA (1) CA2435563A1 (pt)
EA (1) EA006484B1 (pt)
WO (1) WO2002062844A2 (pt)
ZA (1) ZA200305641B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425729D0 (en) * 1994-09-14 1995-02-22 British Telecomm Otical device
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
EA003922B1 (ru) * 1999-05-17 2003-10-30 Конджачем, Инк. Продолжительно действующие инсулинотропные пептиды
EA006160B1 (ru) * 2001-02-16 2005-10-27 Конджачем, Инк. Долгоживущий глюкагоноподобный пептид 2(glp-2, гпп-2) для лечения желудочно-кишечных заболеваний и расстройств
BR0314619A (pt) * 2002-09-18 2005-08-02 Univ Montreal Ct Hospitalier Chum Análogos de ghrh
ATE433999T1 (de) * 2004-04-23 2009-07-15 Conjuchem Biotechnologies Inc Verfahren zur aufreinigung von albumin-konjugaten
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
AU2006329215A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
US20090088380A1 (en) * 2007-07-12 2009-04-02 Pierrette Gaudreau Ghrh analogs and therapeutic uses thereof
EP2231191A2 (en) * 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
US20100267635A1 (en) * 2009-04-20 2010-10-21 Theratechonolgies Inc. Use of protease inhibitors and grf molecules in combination therapy
WO2010121352A1 (en) * 2009-04-20 2010-10-28 Theratechnologies Inc. Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy
PE20121799A1 (es) * 2009-12-21 2013-01-02 Ambrx Inc Polipeptidos de somatotropina porcina modificados y sus usos
WO2011153491A2 (en) 2010-06-03 2011-12-08 University Of Miami Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets
DK2603600T3 (da) 2010-08-13 2019-03-04 Aileron Therapeutics Inc Peptidomimetiske makrocyklusser
JP6113144B2 (ja) * 2011-04-21 2017-04-12 セラテクノロジーズ・インコーポレーテッド 成長ホルモン放出因子（ｇｒｆ）類似体およびその使用
CA2852468A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
US9079974B2 (en) * 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
EP2849567B1 (en) 2012-05-17 2022-03-23 Extend Biosciences, Inc. Carriers for improved drug delivery
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014100809A2 (en) 2012-12-21 2014-06-26 University Of Miami Ghrh agonists for the treatment of ischemic disorders
EP2935317B1 (en) 2012-12-21 2019-03-27 University of Miami Ghrh agonists for islet cell transplantation and function and the treatment of diabetes
CN103897053B (zh) * 2012-12-25 2019-01-15 深圳先进技术研究院 化学修饰的胸腺肽α1及其合成方法
CN103665147A (zh) * 2013-11-26 2014-03-26 深圳翰宇药业股份有限公司 一种生长激素释放因子衍生物的合成方法
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
EP3303378B1 (en) 2015-05-28 2021-04-21 Institut National de la Recherche Scientifique Inhibitors of prototypic galectin dimerization and uses thereof
US20190046604A1 (en) 2015-11-18 2019-02-14 Helmholtz-Zentrum für Infektionsforschung GmbH Labyrinthopeptins as anti-viral agents
WO2017223207A1 (en) 2016-06-22 2017-12-28 University Of Rochester Cyclic peptide inhibitors of hedgehog proteins
US11382950B2 (en) 2016-11-02 2022-07-12 Flagship Pioneering Innovations V, Inc. Compositions and methods for cell delivery
CN108623694B (zh) * 2017-03-24 2021-09-17 北京市肿瘤防治研究所 血管内皮细胞生长因子受体拮抗肽f56的衍生物及应用
WO2022165039A1 (en) 2021-01-28 2022-08-04 Talem Therapeutics Llc Anti-sars-cov-2 spike glycoprotein antibodies and the therapeutic use thereof
WO2024081918A1 (en) 2022-10-14 2024-04-18 Talem Therapeutics Llc Anti-trkb/cd3 antibodies and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4517181A (en) 1982-09-15 1985-05-14 The Salk Institute For Biological Studies Mammalian PGRF
US4563352A (en) 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
US4595676A (en) 1983-04-26 1986-06-17 The Salk Institute For Biological Studies Rat hypothalamic GRF
US4529595A (en) 1983-01-13 1985-07-16 The Salk Institute For Biological Studies GRF Analogs
US4518586A (en) 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
US4628043A (en) 1983-04-26 1986-12-09 The Salk Institute For Biological Studies Hypothalamic GRF agonists
US5416073A (en) * 1983-08-10 1995-05-16 The Adminstrators Of The Tulane Educational Fund Growth hormone-releasing peptides and method of treating animals, therewith
US4605643A (en) 1984-03-02 1986-08-12 The Salk Institute For Biological Studies Ovine GRF
US4585756A (en) 1983-10-12 1986-04-29 The Salk Institute For Biological Studies Bovine GRF
US4610976A (en) 1983-08-29 1986-09-09 The Salk Institute For Biological Studies Porcine GRF
US4626523A (en) 1983-09-13 1986-12-02 The Salk Institute For Biological Studies GRF analogs II
US4528190A (en) 1983-10-25 1985-07-09 The Salk Institute For Biological Studies GRF Analogs IV
EP0189673B1 (en) 1984-12-24 1990-09-26 Sumitomo Pharmaceuticals Company, Limited Stable growth hormone releasing factor preparation
CA1271600A (en) 1985-01-07 1990-07-10 David Howard Coy Growth hormone-releasing peptides and method of treating mammals therewith
US4734399A (en) 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4689318A (en) 1985-08-29 1987-08-25 The Salk Institute For Biological Studies GRF analogs
US4784987A (en) 1987-01-13 1988-11-15 The Salk Institute For Biological Studies GRF analogs VI
US4843064A (en) 1987-01-13 1989-06-27 The Salk Institute For Biological Studies GRF analogs V
WO1989007110A1 (en) 1988-01-28 1989-08-10 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
ATE113607T1 (de) 1988-01-28 1994-11-15 Polygen Holding Corp Polypeptidverbindungen mit wachstumshormonfreisetzender aktivität.
US5756458A (en) 1989-06-16 1998-05-26 Pharmacia & Upjohn Company Stabilized potent GRF analogs
DK608589D0 (da) 1989-12-01 1989-12-01 Holm Arne Kemisk fremgangsmaade
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
DE69226077T2 (de) 1991-04-05 1998-12-03 Genentech Inc PLAETTCHENAGGREGATIONSINHIBITOREN MIT HOHER SPEZIFIZITAET ZUM GP IIbIIIa
EP0542937A1 (en) * 1991-04-09 1993-05-26 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
DE4122210C2 (de) 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
KR950701818A (ko) 1992-06-12 1995-05-17 원본미기재 탈-tyr 다이놀핀 동족체(des-tyr dynorphin analogues)
EP0602290B1 (en) 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
WO1996006626A1 (en) 1994-08-26 1996-03-07 Lee Nancy M Analgesic method with dynorphin analogues truncated at the n-terminus
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
BR9610492A (pt) 1995-09-21 1999-03-30 Andaris Ltd Veículos e intensificadores de transcitose para liberação de droga
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
CN1130222C (zh) * 1996-01-11 2003-12-10 法玛西雅厄普约翰美国公司 水性延长释放配剂
WO1998008872A1 (en) 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-2 derivatives
WO1999024075A2 (en) 1997-11-07 1999-05-20 Conjuchem, Inc. Affinity markers for human serum albumin
CA2309205A1 (en) 1997-11-07 1999-05-20 Conjuchem, Inc. Novel conjugates of rgd-containing peptides and endogenous carriers
CA2291066A1 (en) 1998-03-23 1999-09-30 Conjuchem, Inc. Local delivery of long lasting therapeutic agents
WO2000069900A2 (en) 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
EA003922B1 (ru) 1999-05-17 2003-10-30 Конджачем, Инк. Продолжительно действующие инсулинотропные пептиды
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
DE10012120A1 (de) 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
HUE045882T2 (hu) 2004-03-23 2020-01-28 Ascendis Pharma Gmbh Polimer prodrug önmagát lehasító linkerrel

Also Published As

Publication number Publication date
CN1491233A (zh) 2004-04-21
JP2004520395A (ja) 2004-07-08
CA2435563A1 (en) 2002-08-15
US20030073630A1 (en) 2003-04-17
EA006484B1 (ru) 2005-12-29
JP2009024017A (ja) 2009-02-05
EA200300856A1 (ru) 2004-08-26
CN101696240A (zh) 2010-04-21
EP1355941A2 (en) 2003-10-29
ZA200305641B (en) 2004-05-25
JP2008106073A (ja) 2008-05-08
WO2002062844A2 (en) 2002-08-15
WO2002062844A3 (en) 2003-08-21
US7268113B2 (en) 2007-09-11
AU2002233082B2 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
BR0206919A (pt) Derivados de fator de liberação de hormÈnio de crescimento de longa duração
AU2003299391A1 (en) Edible, chewable object for carnivorous pets and method of controlling the hygiene of the oral cavity of said animals, using one such object
BR0007597A (pt) Composição hipoalergênica contendo peptìdios tolerogênicos induzindo tolerância oral
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
BR9713463A (pt) Fitase de bacillus subtilis, gene codificando a referida fitase, método para a produção e uso da mesma
DE69725052D1 (de) Verbindungsstift für mehrteiliges orthopädisches Implantat
ATE475377T1 (de) Humerusprothese der umgekehrten bauart
ECSP045442A (es) "composiciones y metodo para el tratamiento de infección en ganado vacuno y porcino"
DK1353614T3 (da) Massivt modulsystem
IT1311994B1 (it) Derivati di amminoacidi.
DK1792610T3 (da) Terapeutiske bioadhæsive systemet med langvarig frigivelse
MA27544A1 (fr) Conjugues de l'hormone de croissance humaine chimiquement modifies.
EE200100716A (et) Levodopa / karbidopa / entakapooni farmatseutiline preparaat
NO973745D0 (no) Nukleinsyreholdig preparat, dets fremstilling og anvendelse
BR9910508A (pt) Preparações farmacêuticas estabilizadas de derivados de ácido gama-aminobutìrico e processo para a sua preparação
MXPA05002991A (es) Analogos de ghrh.
BR0313393A (pt) Composição de ração para a alimentação de animais, e, método de alimentação de animais com uma composição de ração
NO20015176L (no) Anvendelse av kreatin som fortilsats
BR0004335A (pt) Substituicão aloplástica para osso longo
BRPI0412332A (pt) método para aumentar nìveis de antioxidante no sangue em um felino, e, composição para dieta adequada para alimentar animais de companhia jovens
TR200101323T2 (tr) Bir ineğe biyolojik olarak sağlanan metioninin temin edilmesi için bir yöntem
AR003687A1 (es) Marca para oreja de animal
SE0203787D0 (sv) Fixtur
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CONJUCHEM BIOTECHNOLOGIES INC. (CA)

Free format text: TRANSFERIDO DE: CONJUCHEM INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal: dismissal of application maintained